Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Alzheimer disease

From inherited to sporadic AD—crossing the biomarker bridge

Nature Reviews Neurology volume 8, pages 598–600 (2012)Cite this article

Subjects

Whether dominantly inherited variants of Alzheimer disease (AD) and 'sporadic' forms exhibit similar pathophysiological and biomarker signatures remains unresolved. A landmark study has proposed a biomarker progression model of dominantly inherited AD, but a complex systems biology and physiology approach is required to translate these findings to sporadic disease.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The genetic and research paradigms of familial AD and sporadic AD.

References

  1. Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795–804 (2012).

    Article  CAS  Google Scholar 

  2. Zetzsche, T., Rujescu, D., Hardy, J. & Hampel, H. Advances and perspectives from genetic research: development of biological markers in Alzheimer's disease. Expert Rev. Mol. Diagn. 10, 667–690 (2010).

    Article  CAS  Google Scholar 

  3. Hampel, H. Lista, S. & Khachaturian, Z. S. Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement. 8, 312–336 (2012).

    Article  CAS  Google Scholar 

  4. Bertram, L. & Hampel, H. The role of genetics for biomarker development in neurodegeneration. Prog. Neurobiol. 95, 501–504 (2011).

    Article  CAS  Google Scholar 

  5. Jack, C. R. Jr et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9, 119–128 (2010).

    Article  CAS  Google Scholar 

  6. Blennow, K., Hampel, H., Weiner, M. & Zetterberg, H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6, 131–144 (2010).

    Article  CAS  Google Scholar 

  7. Faltraco, F., Lista, S., Garaci, F. G. & Hampel, H. Epigenetic mechanisms in Alzheimer's disease: state-of-the-art. Eur. J. Neurodegener. Dis. 1, 1–19 (2012).

    Google Scholar 

  8. Wadman, M. US government sets out Alzheimer's plan. Nature 485, 426–427 (2012).

    Article  CAS  Google Scholar 

  9. Hampel, H. et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat. Rev. Drug Discov. 9, 560–574 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Goethe University, Heinrich-Hoffman Strasse 10, Frankfurt am Main, 60528, Germany

    Harald Hampel & Simone Lista

Authors
  1. Harald Hampel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Simone Lista
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Harald Hampel.

Ethics declarations

Competing interests

H. Hampel has received lecture honoraria and/or research grants and/or travel funding and/or participated in scientific advisory boards of the following pharmaceutical companies that are involved in the manufacture and marketing of diagnostics and/or drugs or medicinal products for Alzheimer disease: Astra-Zeneca, Avid, Bayer, BMS, Boehringer-Ingelheim, Eisai, Elan, Eli Lilly, GE Healthcare, Genentech, GlaxoSmithKline Bio, Janssen-Cilag, Merz Pharmaceuticals, Novartis, Pfizer, Sanofi-Aventis, Schwabe, Roche, and Wyeth. S. Lista declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hampel, H., Lista, S. From inherited to sporadic AD—crossing the biomarker bridge. Nat Rev Neurol 8, 598–600 (2012). https://doi.org/10.1038/nrneurol.2012.202

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2012.202

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research